DK3781550T3 - Bicykliske carboxamider og fremgangsmåder til anvendelse deraf - Google Patents
Bicykliske carboxamider og fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK3781550T3 DK3781550T3 DK19725441.0T DK19725441T DK3781550T3 DK 3781550 T3 DK3781550 T3 DK 3781550T3 DK 19725441 T DK19725441 T DK 19725441T DK 3781550 T3 DK3781550 T3 DK 3781550T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- carboxamides
- bicyclic
- bicyclic carboxamides
- Prior art date
Links
- 150000003857 carboxamides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659068P | 2018-04-17 | 2018-04-17 | |
| US201862746843P | 2018-10-17 | 2018-10-17 | |
| PCT/US2019/027992 WO2019204523A1 (en) | 2018-04-17 | 2019-04-17 | Bicyclic carboxamides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3781550T3 true DK3781550T3 (da) | 2025-01-27 |
Family
ID=66625250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19725441.0T DK3781550T3 (da) | 2018-04-17 | 2019-04-17 | Bicykliske carboxamider og fremgangsmåder til anvendelse deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10968201B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3781550B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7361713B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102815312B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112313208B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019255717B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3096894A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3781550T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3010282T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL277963B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020010879A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202010153WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019204523A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| CN112313208B (zh) | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| WO2022257960A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| CN115448882A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
| WO2024102968A1 (en) * | 2022-11-10 | 2024-05-16 | Tempest Therapeutics, Inc. | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) |
| CN118164967A (zh) * | 2022-12-08 | 2024-06-11 | 武汉人福创新药物研发中心有限公司 | 一种ep2、ep4受体拮抗剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2654811A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8934426B2 (en) | 2009-04-21 | 2015-01-13 | Apple Inc. | Method and apparatus for determining channel quality index in multiple user-MIMO communication networks |
| WO2010121382A1 (en) | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CN103167875A (zh) * | 2010-08-17 | 2013-06-19 | 阿勒根公司 | 用于治疗角膜浑浊的ep2或ep4激动剂 |
| EP2760862B1 (en) * | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105451737B (zh) | 2013-05-23 | 2018-04-10 | 拜耳医药股份有限公司 | 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法 |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
| AU2016370779B2 (en) | 2015-12-17 | 2019-07-25 | Astex Therapeutics Limited | Quinoline-3-carboxamides as H-PGDS inhibitors |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| MX385428B (es) | 2016-07-07 | 2025-03-04 | Ono Pharmaceutical Co | Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| WO2018195123A1 (en) * | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| CN112313208B (zh) | 2018-04-17 | 2024-04-19 | 泰普斯特医疗公司 | 双环羧酰胺及其使用方法 |
| CN115448882A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| US20250179017A1 (en) * | 2022-02-24 | 2025-06-05 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Carboxamide compounds as pge2 receptor antagonists |
-
2019
- 2019-04-17 CN CN201980040841.6A patent/CN112313208B/zh active Active
- 2019-04-17 WO PCT/US2019/027992 patent/WO2019204523A1/en not_active Ceased
- 2019-04-17 JP JP2020555164A patent/JP7361713B2/ja active Active
- 2019-04-17 SG SG11202010153WA patent/SG11202010153WA/en unknown
- 2019-04-17 CA CA3096894A patent/CA3096894A1/en active Pending
- 2019-04-17 MX MX2020010879A patent/MX2020010879A/es unknown
- 2019-04-17 IL IL277963A patent/IL277963B2/en unknown
- 2019-04-17 ES ES19725441T patent/ES3010282T3/es active Active
- 2019-04-17 DK DK19725441.0T patent/DK3781550T3/da active
- 2019-04-17 US US16/387,294 patent/US10968201B2/en active Active
- 2019-04-17 EP EP19725441.0A patent/EP3781550B1/en active Active
- 2019-04-17 KR KR1020207032916A patent/KR102815312B1/ko active Active
- 2019-04-17 AU AU2019255717A patent/AU2019255717B2/en active Active
-
2020
- 2020-10-14 US US17/070,554 patent/US11472789B2/en active Active
-
2022
- 2022-06-23 US US17/847,811 patent/US11795156B2/en active Active
-
2023
- 2023-02-28 AU AU2023201228A patent/AU2023201228A1/en not_active Abandoned
- 2023-09-14 US US18/467,022 patent/US12215093B2/en active Active
-
2024
- 2024-12-19 US US18/988,376 patent/US20250353829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023201228A1 (en) | 2023-04-06 |
| CN112313208A (zh) | 2021-02-02 |
| US20230045612A1 (en) | 2023-02-09 |
| US11795156B2 (en) | 2023-10-24 |
| JP2021521128A (ja) | 2021-08-26 |
| EP3781550A1 (en) | 2021-02-24 |
| US10968201B2 (en) | 2021-04-06 |
| US20250353829A1 (en) | 2025-11-20 |
| KR20210003166A (ko) | 2021-01-11 |
| CN112313208B (zh) | 2024-04-19 |
| JP7361713B2 (ja) | 2023-10-16 |
| MX2020010879A (es) | 2020-11-09 |
| BR112020021042A2 (pt) | 2021-01-19 |
| US11472789B2 (en) | 2022-10-18 |
| US20240150316A1 (en) | 2024-05-09 |
| US20210024491A1 (en) | 2021-01-28 |
| EP3781550B1 (en) | 2024-10-30 |
| US12215093B2 (en) | 2025-02-04 |
| AU2019255717B2 (en) | 2022-12-08 |
| WO2019204523A1 (en) | 2019-10-24 |
| CA3096894A1 (en) | 2019-10-24 |
| ES3010282T3 (en) | 2025-04-02 |
| US20190315712A1 (en) | 2019-10-17 |
| AU2019255717A1 (en) | 2020-11-26 |
| SG11202010153WA (en) | 2020-11-27 |
| IL277963B2 (en) | 2024-09-01 |
| IL277963B1 (en) | 2024-05-01 |
| KR102815312B1 (ko) | 2025-05-30 |
| IL277963A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| IL279965A (en) | Fusion constructs and methods of using thereof | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| EP3809391A4 (en) | CALCULATION DEVICE AND CALCULATION METHOD | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3618928T3 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3901246T3 (da) | Filamentøse svampebiomåtter, fremgangsmåder til fremstilling og fremgangsmåder til anvendelse deraf | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3292150T3 (da) | Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3436022T3 (da) | Oxysteroler og fremgangsmåder til anvendelse heraf | |
| DK3319611T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| IL283782A (en) | Anellosomes and methods of use | |
| EP3961945C0 (en) | DECODING METHODS AND APPARATUS | |
| DK3194328T3 (da) | Gelformpude og fremgangsmåde til fremstilling af samme | |
| DK3652178T3 (da) | Bicykliske ketonforbindelser og fremgangsmåder til anvendelse deraf | |
| PL3554041T3 (pl) | Sposób i urządzenie do określania sekwencji |